LIVIONEX INC. REDEFINES TOOTHPASTE, VIRTUALLY ELIMINATING PLAQUE
~New Dental Gel First to Break Molecular Bond of Plaque, an Oral Health Breakthrough in Combatting America’s Silent Epidemic of Gingivitis and Periodontitis~
San Francisco, July 28, 2014. Livionex, Inc., a Silicon Valley life science company focused on biofilms and inflammation, today released the results of a double blind clinical trial study on reduction of plaque, gingivitis and gum bleeding. The study was conducted at the Beckman Laser Institute of UC Irvine and compared Livionex Dental Gel to Colgate Total, the leading ADA and FDA approved anti-plaque, anti-gingivitis toothpaste.
The results showed an unprecedented 260% reduction in plaque index, 229% reduction in gingivitis index and a 232% reduction in gum bleeding index as compared to Colgate Total. This level of efficacy has never been achieved for an oral hygiene product. The results have been published in the journal “Lasers in Surgery and Medicine.”
Data from both the US Centers for Disease Control and British Medical Journal show that 90% of adults suffer from gingivitis and 47% of all Americans have periodontitis—both caused by plaque. These numbers imply the failure of traditional toothpaste to reduce plaque, which is an oral biofilm. Livionex Dental Gel technology virtually eliminates plaque through daily brushing without the use of any harsh abrasives, detergents or antimicrobials, which are the mainstays of all current toothpaste products on the market.
The Livionex formulation uses activated Edathamil to break up the bond between the plaque biofilm and teeth, thereby interfering with the ability of plaque to stick to teeth. It is also able to reach plaque in gum margins and between teeth. It is this high risk plaque that has been implicated in gingivitis and periodontitis. Oral diseases like periodontitis have been linked to a variety of systemic disease like cardiac disease, arthritis, diabetes and more.
Amit Goswamy, the CEO of Livionex, commented, “We are very pleased with the results of the UC Irvine study and the interest it is generating across the industry. It validates our 10 years of R&D. The Livionex team is excited that the dental gel will pave the way to combat America’s silent epidemic of gingivitis and periodontitis.”
Dr. Peter Jacobson, a well-known dental pharmacologist and Over-the-Counter Dental Products expert said, “Any product that can improve the effectiveness of tooth brushing at a level demonstrated by Livionex is not only a breakthrough, but can be categorized as a disruptive innovation with major public health implications. It redefines what toothpaste and oral hygiene are all about.”
About Livionex
Livionex Inc. was founded in 2009 by Stanford and Berkeley alums with the goal of enhancing the quality and longevity of human life. The company is focused on addressing the role of metal ions in aging and diseases of the human body. The technology is the result of over 10 years of extensive research by key members of the Livionex team in close collaboration with scientists at world renowned research institutions including the University of Texas and the University of California. Livionex is a recipient of prestigious research grants from the US National Institutes of Health (NIH) and the US Department of Defense (DOD). In addition to Livionex Dental Gel, the company is leveraging its technology platform to develop products targeting large unmet medical needs in oral care, ophthalmology and dermatology. The gel is currently available on-line at www.livionexdental.com, select health food stores, and dental offices
Comments